Asset Details
Do you wish to reserve the book?
A novel strategy to target metabolic dependencies in acute myeloid leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A novel strategy to target metabolic dependencies in acute myeloid leukemia
Do you wish to request the book?
A novel strategy to target metabolic dependencies in acute myeloid leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A novel strategy to target metabolic dependencies in acute myeloid leukemia
2025
Overview
Acute myeloid leukemia (AML) remains difficult to cure despite recent advances. Off-target side effects of drugs currently used lead to significant morbidity and mortality. There is recognition that in AML, there is an increased dependence on OXPHOS metabolism, especially in the leukemia stem cell compartment (AML-LSC). It is also recognized that there is potential to exploit this vulnerability to treat AML. Drug re-purposing screens have suggested the potential use of artesunate (ART) to inhibit mitochondrial respiration. We have explored the potential role of ART as an additive agent in treating AML in combination with conventional therapy. Through in-vitro and in-vivo mouse model studies, we demonstrate the mechanism and efficacy of these combinations and their potential to overcome venetoclax resistance. We further demonstrate the specificity of these combinations with minimal off-target effects on normal hematopoietic stem cells (HSC). These observations warrant exploration of the additive role of ART in clinical trials.
Publisher
Nature Publishing Group UK,Springer Nature B.V,Nature Publishing Group
Subject
/ 13/106
/ 13/31
/ 14/1
/ 14/28
/ 631/154
/ 631/80
/ 82/58
/ 82/79
/ Animals
/ Artesunate - therapeutic use
/ Biomedical and Life Sciences
/ Bridged Bicyclo Compounds, Heterocyclic - pharmacology
/ Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
/ Drug Resistance, Neoplasm - drug effects
/ Glucose
/ Hematopoietic Stem Cells - drug effects
/ Hematopoietic Stem Cells - metabolism
/ Humans
/ Leukemia
/ Leukemia, Myeloid, Acute - drug therapy
/ Leukemia, Myeloid, Acute - metabolism
/ Leukemia, Myeloid, Acute - pathology
/ Mice
/ Neoplastic Stem Cells - drug effects
/ Neoplastic Stem Cells - metabolism
/ Neoplastic Stem Cells - pathology
/ Oxidative Phosphorylation - drug effects
/ Proteins
/ Protons
